Patterns of Viral Arthropathy and Myalgia Following COVID-19: A Cross-Sectional National Survey
Open Access
- 29 September 2022
- journal article
- research article
- Published by Taylor & Francis in Journal of Pain Research
- Vol. ume 15, 3069-3077
Abstract
Introduction: Viral arthropathy is an increasingly recognized sequela of several viral pathogens including alphaviruses, hepatitis, and potentially coronaviruses. Case reports of viral arthropathy and myalgia associated with SARS-CoV-2 infection (COVID-19) both during active disease and following resolution of acute COVID-19 symptoms are becoming more prevalent. We sought to describe the prevalence of viral arthropathy and myalgia associated with COVID-19, as well as to identify factors that may predict these symptoms. Methods: A national, cross-sectional survey was conducted using a questionnaire administered online. Subjects self-reporting previous confirmed COVID-19 were recruited using the Amazon Mechanical Turk crowdsourcing platform. Questionnaire items included demographics, frequency and severity of common COVID-19 symptoms, requirement for hospitalization or mechanical ventilation, subject recall of arthropathy or myalgia onset, duration, and severity, as well as WOMAC score. Binary logistic regression was used to identify potential predictive co-variates for the development of either arthropathy or myalgia. Results: A total of 3222 participants completed the arthropathy/myalgia questionnaire with 1065 responses remaining for analysis following application of exclusion criteria, data integrity review, and omission of respondents with confounding conditions. Of the 1065 cases, 282 (26.5%) reported arthralgia and 566 (53.2%) reported myalgia at some point during or after COVID-19 with 9.9% and 6.0% reporting onset of arthralgia or myalgia, respectively, after resolution of acute COVID-19 symptoms. The presence of several commonly reported COVID symptoms or indicators of disease severity was predictive of arthralgia including hospitalization (OR 3.7; 95% CI 2.4 to 5.8), sore throat (OR 2.3; 95% CI 1.5 to 3.5), fatigue (OR 2.9; 95% CI 1.7 to 4.9), and ageusia/anosmia (OR 1.7; 95% CI 1.1 to 2.7). Discussion: Based on these results, new-onset arthropathy and myalgia following COVID-19 resolution may be an increasingly encountered etiology for pain.Keywords
This publication has 24 references indexed in Scilit:
- Expanding the CONSORT Figure: Increasing Transparency in Reporting on External ValidityAmerican Journal of Preventive Medicine, 2018
- Reactive arthritis: update 2018Clinical Rheumatology, 2018
- Using Mechanical Turk to recruit participants for internet intervention research: experience from recruitment for four trials targeting hazardous alcohol consumptionBMC Medical Research Methodology, 2017
- SARS and MERS: recent insights into emerging coronavirusesNature Reviews Microbiology, 2016
- Viral arthritisClinical Medicine, 2016
- The immunobiology of viral arthritidesPharmacology & Therapeutics, 2009
- Viral myositis leading to rhabdomyolysis: a case report and literature reviewThe American Journal of Emergency Medicine, 2009
- Virally associated arthritis 2008: clinical, epidemiologic, and pathophysiologic considerationsArthritis Research & Therapy, 2008
- The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC): a review of its utility and measurement propertiesArthritis & Rheumatism, 2001
- The CONSORT Statement: Revised Recommendations for Improving the Quality of Reports of Parallel-Group Randomized TrialsAnnals of Internal Medicine, 2001